Next 10 |
2024-05-01 14:28:11 ET A California-based %Biotech company is turning heads on Wednesday after it announced that it entered into a research collaboration and license agreement with Astellas Pharma’s Xyphos Biosciences subsidiary. Shares of %PoseidaTherapeutics (Nasdaq: $P...
2024-05-01 13:54:38 ET Poseida Therapeutics ( NASDAQ: PSTX ) shares traded higher on Wednesday after the company and Japanese drugmaker Astellas ( OTCPK:ALPMY ) announced a partnership to develop and commercialize CAR-T cell therapies for cancer.... Read the full article o...
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire - Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs tar...
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting PR Newswire Company to deliver three oral and three poster presentations highlighting its portfolio of non-viral genetic medicines Present...
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus PR Newswire Fully non-viral approach to genetic m...
2024-04-16 10:00:22 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Shor...
2024-04-15 17:21:24 ET Gainers: Macatawa Bank Corporation ( MCBC ) +38% . Biomea Fusion ( BMEA ) +5% . The RealReal ( REAL ) +4% . Cartesian Therapeutics ( RNAC ) +3% . Construction Partners ( ROAD ) +3% . Losers: Poseida...
2024-04-08 17:16:31 ET More on Poseida Therapeutics Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement Poseida spikes after FDA orphan status for CAR-T therapy Read the full article on Seeking Alpha For further details see: Pose...
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma PR Newswire Promising early data suggest patients with relapsed/refractory multiple myeloma...
2024-03-26 16:42:37 ET Gainers: nCino ( NCNO ) +14% . Biomea Fusion ( BMEA ) +7% . Poseida Therapeutics ( PSTX ) +5% . Office Properties Income ( OPI ) +5% . Canopy Growth Corporation ( CGC ) +4% . Losers: Bow...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
2024-05-01 14:28:11 ET A California-based %Biotech company is turning heads on Wednesday after it announced that it entered into a research collaboration and license agreement with Astellas Pharma’s Xyphos Biosciences subsidiary. Shares of %PoseidaTherapeutics (Nasdaq: $P...
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire - Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs tar...
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting PR Newswire Company to deliver three oral and three poster presentations highlighting its portfolio of non-viral genetic medicines Present...